The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer.
Yelena Yuriy Janjigian
Research Funding - Boehringer Ingelheim
Marinela Capanu
No relevant relationships to disclose
Christopher M. Gromisch
No relevant relationships to disclose
David Paul Kelsen
No relevant relationships to disclose
Geoffrey Y. Ku
No relevant relationships to disclose
Karen T. Brown
No relevant relationships to disclose
Mark Schattner
No relevant relationships to disclose
David H. Ilson
No relevant relationships to disclose
David B. Solit
No relevant relationships to disclose
Michael F. Berger
No relevant relationships to disclose
Efsevia Vakiani
No relevant relationships to disclose